Document Classification

Section Type: RESULTS

Text: During the follow-up period, in the intention-to-treat analysis, 92 % of the patients receiving low-dose posaconazole and 81 % receiving high-dose posaconazole, as compared with 38 % receiving benznidazole, tested positive for T. cruzi DNA on rt-PCR assay (P < 0. 01 for the comparison of the benznidazole group with either posaconazole group) ; in the per-protocol analysis, 90 % of the patients receiving low-dose posaconazole and 80 % of those receiving high-dose posaconazole, as compared with 6 % receiving benznidazole, tested positive on rt-PCR assay (P < 0. 001 for the comparison of the benznidazole group with either posaconazole group).